Crestor Safety Data Under FDA Review; 11 Reports Of Rhabdomyolysis At 10 Mg Dose

The agency appears unlikely to make a significant change in the regulatory status of the statin in the near term; FDA notes that most of the reported cases of rhabdomyolysis and renal failure could be attributed to the underlying disease or concomitant medications. Public Citizen renews call for Crestor's withdrawal in Lancet article.